Takeda Pharmaceutical CO LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Takeda Pharmaceutical Company Limited and its subsidiary Takeda Pharmaceuticals U.S.A., Inc. have filed an amendment to their beneficial ownership of Ovid Therapeutics Inc., reporting an aggregate stake of 12.3%.